In the last trading session, 1.08 million C4 Therapeutics Inc (NASDAQ:CCCC) shares changed hands as the company’s beta touched 3.05. With the company’s per share price at $5.56 changed hands at -$0.14 or -2.46% during last session, the market valuation stood at $385.53M. CCCC’s last price was a discount, traded about -113.67% off its 52-week high of $11.88. The share price had its 52-week low at $1.06, which suggests the last value was 80.94% up since then. When we look at C4 Therapeutics Inc’s average trading volume, we note the 10-day average is 0.98 million shares, with the 3-month average coming to 1.26 million.
Analysts gave the C4 Therapeutics Inc (CCCC) stock a consensus recommendation rating of Hold, calculated at a mean rating of 1.75. If we narrow down to specifics, the data shows that 0 out of 3 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 2 recommended CCCC as a Hold, 1 felt it is a Buy and 0 rated the stock as Underweight. C4 Therapeutics Inc’s EPS for the current quarter is expected to be -0.38.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
C4 Therapeutics Inc (NASDAQ:CCCC) trade information
Instantly CCCC was in red as seen at the end of in last trading. With action -11.46%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -1.59%, with the 5-day performance at -11.46% in the red. However, in the 30-day time frame, C4 Therapeutics Inc (NASDAQ:CCCC) is -12.03% down. Looking at the short shares, we see there were 11.92 million shares sold at short interest cover period of 10.05 days.
The consensus price target for the stock as assigned by Wall Street analysts is 12.5, meaning bulls need an upside of 55.52% from its current market value. According to analyst projections, CCCC’s forecast low is 9 with 20 as the target high. To hit the forecast high, the stock’s price needs a -259.71% plunge from its current level, while the stock would need to soar -61.87% for it to hit the projected low.
C4 Therapeutics Inc (CCCC) estimates and forecasts
Data shows that the C4 Therapeutics Inc share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -27.60% over the past 6 months, a 41.20% in annual growth rate that is considerably higher than the industry average of 17.80%. Year-over-year growth is forecast to reach 37.00% up from the last financial year.
Consensus estimates given by 5 financial analysts project the company’s revenue in the current quarter to hit an average of 4.6M. 5 analysts are of the opinion that C4 Therapeutics Inc’s revenue for the current quarter will be 4.12M. The company’s revenue for the corresponding quarters a year ago was 5.46M and 3.26M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -15.80%. The estimates for the next quarter sales put growth at 26.30%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -36.05%. The 2024 estimates are for C4 Therapeutics Inc earnings to increase by 46.93%, but the outlook for the next 5-year period is at 22.30% per year.
CCCC Dividends
C4 Therapeutics Inc is expected to release its next quarterly earnings report in November.
C4 Therapeutics Inc (NASDAQ:CCCC)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 11.65% of C4 Therapeutics Inc shares while 88.47% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 100.14%. There are 88.47% institutions holding the C4 Therapeutics Inc stock share, with LYNX1 CAPITAL MANAGEMENT LP the top institutional holder. As of 2024-06-30, the company held 9.9993% of the shares, roughly 6.88 million CCCC shares worth $31.79 million.
RA CAPITAL MANAGEMENT, L.P. holds the second largest percentage of outstanding shares, with 7.0891% or 4.88 million shares worth $22.54 million as of 2024-06-30.
